GeneDx Shares Surge on Strong Quarterly Performance and Confirmed Outlook

GeneDx Q4 earnings beat estimates with $0.14 EPS and $121M revenue, up 27%. Strong volume growth and pricing power drive robust outlook for 2026.

GeneDx has capped off its 2025 fiscal year with robust fourth-quarter results that surpassed market forecasts. The company’s financial momentum is being fueled by significant demand for its genomic testing services and improving reimbursement rates, setting a positive tone for the year ahead.

Exceeding Expectations on Profit and Sales

A key highlight was the company’s performance on profitability. GeneDx reported an adjusted earnings per share of $0.14, outperforming the $0.11 consensus estimate from analysts. This was supported by a stabilized adjusted gross margin, which remained at a high level of 71%.

Revenue for the quarter climbed 27% year-over-year to $121.0 million. For the full year, total revenue saw a substantial 41% increase, reaching $427.5 million. Driving this growth was the core exome and genome testing business, which contributed $104.0 million in Q4 alone—a 32% jump from the prior-year period. Excluding one-time effects from the previous year, the organic growth rate for this segment was even more impressive at 42%.

Volume Growth and Pricing Power

The company’s test volume exhibited strong expansion, reinforcing the top-line results. During the reporting period, GeneDx conducted 27,761 exome and genome tests, representing a volume increase of 34.3%. Alongside higher volumes, the average revenue per test continues to demonstrate positive momentum. The company now realizes approximately $3,750 per test on average, marking a steady rise from $2,500 in 2023 and $3,000 in 2024.

Analyst Sentiment and Strategic Expansion

Following the earnings release, BTIG Research reaffirmed its Buy rating on GeneDx shares. However, the firm adjusted its price target downward to $170 from $200. The company enters its new fiscal year from a position of financial strength, with cash and cash equivalents totaling $172.3 million as of year-end 2025.

Management has outlined an aggressive strategy to capture further market share. Plans for 2026 include a major expansion of the sales force, aiming to add approximately 100 new positions. This initiative would nearly triple the team to a total of 160 representatives.

Confirmed Guidance for the Coming Year

The financial outlook for 2026 remains firmly on track, as confirmed by the latest report. GeneDx anticipates full-year revenue in the range of $540 million to $555 million. This projection is underpinned by an expected volume growth rate of 33% to 35% for its core testing services. The company also forecasts achieving a positive adjusted net income for the period, signaling continued progress toward sustainable profitability.